Emgality

Chemical Namegalcanezumab-gnlm
Dosage FormInjection (subcutaneous; 120 mg, 300 mg)
Drug ClassMonoclonal antibodies
SystemNervous
CompanyEli Lilly and Company
Approval Year2018

Indication

  • The prevention of migraines in adults.
Last updated on 11/11/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Emgality (Galcanezumab-gnlm) Prescribing Information 2018Eli Lilly and Company, Indianapolis, IN